Sen­sei Bio­ther­a­peu­tics rakes in $28.5M to give can­cer im­munother­a­pies a push

Less than a month af­ter of­fer­ing a glimpse at ear­ly clin­i­cal da­ta for its lead can­cer im­munother­a­py at vir­tu­al ES­MO, Sen­sei Bio­ther­a­peu­tics has reeled in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER